Evidence map›Paper›PMID 33240395›Full record

ArticleTherapeutic advances in gastroenterology2020

Self-assessment of treatment targets in patients with inflammatory bowel disease using a survey.

Philipp A Reuken, Philip C Grunert, Andreas Lügering, Niels Teich, Andreas Stallmach

Abstract read
In one paragraph

Article in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Philipp A ReukenKlinik für Innere Medizin IV - Gastroenterologie, Hepatologie, Infektiologie, Universitätsklinikum Jena, Am Klinikum 1, Jena, 07747, Germany.ORCID https://orcid.org/0000-0002-7696-475X
Philip C GrunertDepartment of Internal Medicine IV, Jena University Hospital, Jena, Germany.
Andreas LügeringZentrum für Leber-, Magen- und Darmerkrankungen, Medizinisches Versorgungszentrum Portal 10, Münster, Germany.
Niels TeichInternistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten Leipzig und Schkeuditz, Leipzig, Germany.
Andreas StallmachDepartment of Internal Medicine IV, Jena University Hospital, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhysicians can improve their relationships with patients by understanding and meeting patients' treatment targets, leading to higher adherence to therapy and improved disease prognosis. In the current study, we performed a questionnaire-based survey to further understand treatment targets in patients with inflammatory bowel disease (IBD).

methodsWe created a questionnaire based on a point-allocation scale with 10 treatment target items. A total of 234 patients with IBD [Crohn's disease (

resultsThe most important treatment targets for patients regarding their therapy were quality of life (2.78 points), control of defecation (1.53 points), and avoidance of IBD-related surgery (1.69 points). Avoiding surgery for IBD was less important in patients who had already undergone a surgical procedure than in those who had not (1.26 points

conclusionTreatment targets for patients were primarily related to quality of life, such as therapy side effects. Knowing these targets may improve patient-physician relationships and communication, and consequently, adherence to therapy.

Indexed as

communicationinflammatory bowel diseasepatients’ perspectivesurvey

Identifiers

PMID33240395
PMCPMC7675909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.